Sale!

CYLD Gene Cylindromatosis Familial NGS Genetic DNA Test

Original price was: $700.Current price is: $500.

-29%

The CYLD Gene Cylindromatosis Familial NGS Genetic DNA Test is a comprehensive genetic screening that identifies mutations in the CYLD gene associated with familial cylindromatosis. This hereditary condition significantly increases the risk of developing multiple skin tumors and other cancer types. Using advanced Next-Generation Sequencing (NGS) technology, this test provides precise detection of genetic variants that may predispose individuals to cancer development. The test is particularly important for individuals with a family history of multiple skin tumors, especially those appearing on the scalp, face, and neck. Early identification of CYLD gene mutations enables proactive monitoring and personalized cancer prevention strategies. Results are typically available within 3-4 weeks from sample collection. The test is priced at $500 USD with genetic counseling included to help interpret results and develop appropriate management plans.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

CYLD Gene Cylindromatosis Familial NGS Genetic DNA Test

Comprehensive Genetic Assessment for Hereditary Cancer Risk

The CYLD Gene Cylindromatosis Familial NGS Genetic DNA Test represents a cutting-edge approach to identifying individuals at risk for hereditary cancer syndromes. This specialized genetic test focuses on detecting mutations in the CYLD gene, which plays a crucial role in tumor suppression and cellular regulation. Familial cylindromatosis is an autosomal dominant condition characterized by the development of multiple benign skin tumors called cylindromas, primarily affecting the scalp, face, and neck regions.

What Does This Test Measure?

Our advanced NGS-based test comprehensively analyzes the CYLD gene for pathogenic variants that are associated with:

  • Familial cylindromatosis (Brooke-Spiegler syndrome)
  • Increased susceptibility to multiple skin tumors
  • Potential risk for other associated malignancies
  • Genetic mutations affecting tumor suppressor function

The test utilizes Next-Generation Sequencing technology to provide high-resolution analysis of the entire CYLD gene coding region, including exon-intron boundaries and known regulatory elements. This comprehensive approach ensures maximum detection sensitivity for clinically relevant variants.

Who Should Consider This Test?

This genetic test is particularly recommended for individuals experiencing or concerned about:

  • Multiple skin tumors, especially on the scalp and face
  • Family history of cylindromas or trichoepitheliomas
  • Early-onset skin tumors in multiple family members
  • Personal history of multiple benign skin growths
  • Family members of individuals diagnosed with CYLD mutations
  • Unexplained skin tumor development in childhood or early adulthood

Clinical Benefits of Testing

Undergoing the CYLD Gene Cylindromatosis Familial NGS Genetic DNA Test provides numerous advantages:

  • Early Risk Identification: Detect genetic predisposition before symptom development
  • Personalized Monitoring: Implement targeted surveillance protocols
  • Family Planning Guidance: Make informed reproductive decisions
  • Proactive Management: Develop preventive strategies for at-risk individuals
  • Psychological Relief: Reduce uncertainty through definitive genetic information
  • Treatment Planning: Guide appropriate medical and surgical interventions

Understanding Your Test Results

Your genetic test results will fall into one of several categories:

  • Positive Result: Indicates the presence of a known pathogenic CYLD gene mutation, confirming increased cancer risk and necessitating regular monitoring
  • Negative Result: No mutation detected in the CYLD gene, significantly reducing hereditary cancer risk
  • Variant of Uncertain Significance (VUS): Identifies a genetic change with unknown clinical implications, requiring ongoing research and family studies
  • Benign Variant: Common genetic variations with no known disease association

All results are accompanied by comprehensive genetic counseling to ensure proper interpretation and appropriate next steps. Our certified genetic counselors will help you understand the implications of your results and develop a personalized management plan.

Test Pricing and Details

Test Component Price (USD)
Discount Price $500
Regular Price $700

Additional Test Information:

  • Turnaround Time: 3 to 4 Weeks
  • Sample Type: Blood, Extracted DNA, or One Drop Blood on FTA Card
  • Pre-test Requirements: Clinical history documentation and genetic counseling session
  • Specialty: Oncology Genetics
  • Methodology: Next-Generation Sequencing (NGS) Technology

Nationwide Accessibility

We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, and many other cities. Our network of certified genetic counselors and healthcare providers ensures you receive consistent, high-quality care regardless of your location.

Take the Next Step Toward Genetic Clarity

Understanding your genetic risk for hereditary cancer syndromes is a powerful step toward proactive health management. Our comprehensive CYLD Gene Cylindromatosis Familial NGS Genetic DNA Test provides the clarity and confidence you need to make informed healthcare decisions.

Ready to schedule your test? Contact our genetic counseling team today at +1(267) 388-9828 or book your appointment online. Our dedicated specialists are available to answer your questions and guide you through the testing process with compassion and expertise.

Don’t let uncertainty about your genetic health cloud your future. Take control of your health journey with definitive genetic testing from General Genetics Corporation – your trusted partner in personalized genetic medicine.